Preclinical studies have demonstrated that in vitro and in vivo inhibition of ErbB receptor tyrosine kinase activity with tyrosine kinase inhibitors (21, 22) or genetic manipulation (23) and/or reduced ErbB ligand availability (24) significantly reduced cyst formation and enlargement. This evidence concerns the gene EGFR and cyst.